世界のバイオテクノロジー&製薬におけるサービスアウトソーシング市場2021-2028:サービス別(コンサルティング、規制関連業務)、最終用途別(製薬、バイオテクノロジー)

調査会社Grand View Research社が発行したリサーチレポート(データ管理コード:GV21MC006)
◆英語タイトル:Biotechnology & Pharmaceutical Services Outsourcing Market Size, Share & Trends Analysis Report By Service (Consulting, Regulatory Affairs), By End-use (Pharma, Biotech), And Segment Forecasts, 2021 - 2028
◆発行会社/調査会社:Grand View Research
◆商品コード:GV21MC006
◆発行日:2021年2月26日
◆調査対象地域:グローバル
◆産業分野:サービス
◆ページ数:110
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール(受注後3営業日)
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥654,500見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥764,500見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥984,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Grand View Research社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[世界のバイオテクノロジー&製薬におけるサービスアウトソーシング市場2021-2028:サービス別(コンサルティング、規制関連業務)、最終用途別(製薬、バイオテクノロジー)]についてメールでお問い合わせはこちら
グランドビューリサーチ社は、世界のバイオテクノロジー&製薬におけるサービスアウトソーシング市場規模が年平均5.2%成長し、2028年までに914億ドルに達すると予測しています。本調査レポートでは、バイオテクノロジー&製薬におけるサービスアウトソーシングの世界市場について調査・分析し、調査手法・範囲、エグゼクティブサマリー、市場変動・動向・範囲、サービス別(コンサルティング、監査・評価、規制関連業務、製品メンテナンス、製品設計・開発)分析、最終用途別(製薬、バイオテクノロジー)分析、地域別分析、競争状況、企業情報などを掲載しています。
・調査手法・範囲
・エグゼクティブサマリー
・市場変動・動向・範囲
・バイオテクノロジー&製薬におけるサービスアウトソーシングの世界市場規模:サービス別(コンサルティング、監査・評価、規制関連業務、製品メンテナンス、製品設計・開発)
・バイオテクノロジー&製薬におけるサービスアウトソーシングの世界市場規模:最終用途別(製薬、バイオテクノロジー)
・バイオテクノロジー&製薬におけるサービスアウトソーシングの世界市場規模:地域別
・競争状況
・企業情報
*** レポート概要(サマリー)***

Biotechnology & Pharmaceutical Services Outsourcing Market Growth & Trends

The global biotechnology and pharmaceutical services outsourcing market size is expected to reach USD 91.4 billion by 2028 registering a CAGR of 5.2%, according to a new report by Grand View Research, Inc. The high demand for biologics along with small molecules has led to the expansion of service portfolios of Contract Manufacturing Organizations (CMOs)/Contract Research Organizations (CROs) for biotechnology and pharmaceutical production. Small pharma/biotech companies are facing challenges while performing in-house development, regulatory affairs, product maintenance, product design & development, product testing & validation, and training & education, such as lack of substantial expertise and expensive capability. This, in turn, has created lucrative opportunities for the growth of CMOs & CROs. Contract services are growing and becoming strategic, targeted, and planned. These factors are expected to play a pivotal role in enhancing the share of CMOs/CROs in the overall market.

Growing pricing pressure, regulatory challenges, and patent expiration have led to shrinking margins in the biotech and pharmaceutical industry. Contract services offer cost saving to their clients and also help save time utilized in operations and management of a production & research facility. Furthermore, outsourcing services assist in overcoming trade barriers and facilitate the entry of firms into foreign markets. Owing to these advantages, several firms choose to outsource services rather than investing capital in production equipment and hiring skilled labor.

The coronavirus outbreak is having a considerable impact on biotech and pharma third-party service providers as well as clinical trials, resulting in trial delays, suspensions, and terminations. The global crisis has emphasized the need for virtual trials and leveraging on technology & software solutions. Increasing adoption of machine learning-based platforms & Artificial Intelligence (AI), innovative trial designs, and automation in drug manufacturing are projected to transform the CRO and CMO landscape in the coming years. Biopharmaceutical & pharmaceutical investments in novel and innovative therapies, for instance, regenerative medicine, are driving the R&D activity together with drug development services.

The biologics industry has grown substantially in recent years to include novel product types including nanobodies, rDNA, synthetic vaccines, fusion proteins, soluble receptors, immunoconjugates, and immunotherapeutics. Owing to the revolutionization of disease therapy through biologics, this sector has also provided many opportunities to explore hybrid structures that combine biologics with well-defined chemical entities. The significant growth of biologics is expected to drive the demand for outsourcing of biologics development and manufacturing.

Biotechnology & Pharmaceutical Services Outsourcing Market Report Highlights

• The consulting service segment led the market in 2020 and will retain its dominant position throughout the forecast period

• Biotechnology and pharmaceutical companies are increasingly opting for consulting services due to factors, such as the increasing number of fraudulent cases and discrepancies in intellectual property rights

• The pharma end-use segment is expected to lead the market in terms of revenue share as well as CAGR over the forecast period as the pharma companies outsource internal activities at a larger scale due to rising pricing pressure and increasing competition

• North America was the dominant regional market in 2020 due to the presence of biotechnology and pharmaceutical companies and the high quality of services offered by the CROs and CMOs in the region

• However, Asia Pacific is anticipated to register the fastest CAGR over the forecast period owing to improved regulatory frameworks, the high scope for cost savings, availability of cheap labor & skilled personnel, and rapid growth of the biotechnology and pharmaceutical industry in the region

*** レポート目次(コンテンツ)***

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Service
1.1.2 End-Use
1.1.3 Regional Scope
1.1.4 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.3.5.1 Data for Primary Interviews in North America
1.3.5.2 Data for Primary Interviews in Europe
1.3.5.3 Data for Primary Interviews in Asia Pacific
1.3.5.4 Data for Primary Interviews in Latin America
1.3.5.5 Data for Primary Interviews in MEA
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.2 Volume Price Analysis (Model 2)
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective – 1:
1.10.2 Objective – 2:
1.10.3 Objective – 3:
1.10.4 Objective – 4:
Chapter 2 Executive Summary
2.1 Market Outlook
Chapter 3 Biotechnology & Pharmaceutical services Outsourcing Market: Variables, Trends, & Scope
3.1 Market Segmentation and Scope
3.2 Market Driver Analysis
3.2.1 Increasing outsourcing of R&D activities
3.2.2 Changing regulatory landscape
3.2.3 Increasing focus on core competencies by pharmaceutical and biotechnology companies
3.2.4 Growing drug development costs coupled with high clinical development failure rates
3.2.5 Increasing mergers and collaborations
3.3 Market Restraint Analysis
3.3.1 Monitoring issues and lack of standardization
3.3.2 Loss of control
3.3.3 Data security issues
3.4 Penetration & Growth Prospect Mapping
3.5 Porter’s Five Forces Analysis
3.6 PESTEL Analysis
3.7 End-use Perception Analysis
3.7.1 Why do you outsource Biotechnology & Pharmaceutical services to CROs?
3.7.2 Percentage of outsourcing of different services.
3.7.3 Importance of CRO selection parameters (Ranking from 1 to 5, where 1 – least important and 5 – most important).
3.8 Service Price Analysis
3.8.1 Pricing strategy
3.8.1.1 Transactional business models
3.8.1.2 Performance-based business models
3.8.1.3 Outcome-based business models
3.8.2 Consulting rates
3.8.3 Heat map for pricing analysis
Chapter 4 Biotechnology & Pharmaceutical services Outsourcing Market: Service Segment Analysis
4.1 Biotechnology & Pharmaceutical services Outsourcing: Market Share Analysis, 2020 & 2028
4.2 Consulting
4.2.1 Consulting Market, 2016 – 2028 (USD Million)
4.2.2 Regulatory compliance
4.2.2.1 Regulatory compliance market, 2016 – 2028 (USD Million)
4.2.3 Remediation
4.2.3.1 Remediation market, 2016 – 2028 (USD Million)
4.2.4 Quality Management Systems Consulting
4.2.4.1 Quality management systems consulting market, 2016 – 2028 (USD Million)
4.2.5 Others
4.2.5.1 Others market, 2016 – 2028 (USD Million)
4.3 Auditing & Assessment
4.3.1 Auditing & assessment market, 2016 – 2028 (USD Million)
4.4 Regulatory Affairs
4.4.1 Regulatory affairs market, 2016 – 2028 (USD Million)
4.4.2 Clinical Trial Applications & Product Registration
4.4.2.1 Clinical trial applications & product registration market, 2016 – 2028 (USD Million)
4.4.3 Regulatory Writing & Publishing
4.4.3.1 Regulatory writing & publishing market, 2016 – 2028 (USD Million)
4.4.4 Legal Representation
4.4.4.1 Legal representation market, 2016 – 2028 (USD Million)
4.4.5 Others
4.4.5.1 Others market, 2016 – 2028 (USD Million)
4.5 Product Maintenance
4.5.1 Product maintenance market, 2016 – 2028 (USD Million)
4.6 Product Design & Development
4.6.1 Product Design & Development market, 2016 – 2028 (USD Million)
4.7 Product Testing & Validation
4.7.1 Product Testing & Validation market, 2016 – 2028 (USD Million)
4.8 Training & Education
4.8.1 Training & Education market, 2016 – 2028 (USD Million)
4.9 Others
4.9.1 Others market, 2016 – 2028 (USD Million)
Chapter 5 Biotechnology & Pharmaceutical services Outsourcing Market: End-use Segment Analysis
5.1 Biotechnology & Pharmaceutical services Outsourcing: Market Share Analysis, 2020 & 2028
5.2 Pharmaceutical Companies
5.2.1 Pharmaceutical Companies market, 2016 – 2028 (USD Million)
5.3 Biotech Companies
5.3.1 Biotech Companies market, 2016 – 2028 (USD Million)
Chapter 6 Biotechnology & Pharmaceutical services Outsourcing Market: Regional Analysis
6.1 Biotechnology & Pharmaceutical services Outsourcing: Market Share Analysis, 2020 & 2028
6.2 North America
6.2.1 North America Market, 2016 – 2028 (USD Million)
6.2.2 The U.S.
6.2.2.1 The U.S. Market, 2016 – 2028 (USD Million)
6.2.3 Canada
6.2.3.1 Canada Market, 2016 – 2028 (USD Million)
6.3 Europe
6.3.1 Europe Market, 2016 – 2028 (USD Million)
6.3.2 The U.K.
6.3.2.1 The U.K. Market, 2016 – 2028 (USD Million)
6.3.3 Germany
6.3.3.1 Germany Market, 2016 – 2028 (USD Million)
6.3.4 France
6.3.4.1 France Market, 2016 – 2028 (USD Million)
6.3.5 Italy
6.3.5.1 Italy Market, 2016 – 2028 (USD Million)
6.3.6 Spain
6.3.6.1 Spain Market, 2016 – 2028 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific Market, 2016 – 2028 (USD Million)
6.4.2 Japan
6.4.2.1 Japan Market, 2016 – 2028 (USD Million)
6.4.3 China
6.4.3.1 China Market, 2016 – 2028 (USD Million)
6.4.4 India
6.4.4.1 India Market, 2016 – 2028 (USD Million)
6.4.5 Australia
6.4.5.1 Australia Market, 2016 – 2028 (USD Million)
6.4.6 South Korea
6.4.6.1 South Korea Market, 2016 – 2028 (USD Million)
6.5 Latin America
6.5.1 Latin America market, 2016 – 2028 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil market, 2016 – 2028 (USD Million)
6.5.3 Mexico
6.5.3.1 Mexico market, 2016 – 2028 (USD Million)
6.5.4 Argentina
6.5.4.1 Argentina market, 2016 – 2028 (USD Million)
6.6 MEA
6.6.1 MEA market, 2016 – 2028 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa market, 2016 – 2028 (USD Million)
6.6.3 Saudi Arabia
6.6.3.1 Saudi Arabia market, 2016 – 2028 (USD Million)
6.6.4 UAE
6.6.4.1 UAE market, 2016 – 2028 (USD Million)
Chapter 7 Competitive Landscape
7.1 Strategy Framework
7.2 Company Profiles
7.2.1 The Quantic Group
7.2.1.1 Company overview
7.2.1.2 Financial performance
7.2.1.3 Service benchmarking
7.2.2 IQVIA Holdings, Inc.
7.2.2.1 Company overview
7.2.2.2 Financial performance
7.2.2.3 Service benchmarking
7.2.2.4 Strategic Initiatives
7.2.3 Parexel International Corporation
7.2.3.1 Company overview
7.2.3.2 Financial performance
7.2.3.3 Service benchmarking
7.2.3.4 Strategic Initiatives
7.2.4 Lachman Consultant Services
7.2.4.1 Company overview
7.2.4.2 Financial performance
7.2.4.3 Service benchmarking
7.2.5 GMP Pharmaceuticals
7.2.5.1 Company overview
7.2.5.2 Financial performance
7.2.5.3 Service benchmarking
7.2.5.4 Strategic Initiatives
7.2.6 Concept Heidelberg GmbH
7.2.6.1 Company overview
7.2.6.2 Financial performance
7.2.6.3 Service benchmarking
7.2.7 Covance, Inc.
7.2.7.1 Company overview
7.2.7.2 Financial performance
7.2.7.3 Service benchmarking
7.2.8 Charles River
7.2.8.1 Company overview
7.2.8.2 Financial performance
7.2.8.3 Service benchmarking
7.2.8.4 Strategic Initiatives
7.2.9 PRA Health Sciences
7.2.9.1 Company overview
7.2.9.2 Financial performance
7.2.9.3 Service benchmarking
7.2.9.4 Strategic Initiatives
7.2.10 ICON plc
7.2.10.1 Company overview
7.2.10.2 Financial performance
7.2.10.3 Service benchmarking
7.2.10.4 Strategic Initiatives


List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global Biotechnology & Pharmaceutical services Outsourcing Market, by Region, 2016 - 2028 (USD Million)
Table 4 Global Biotechnology & Pharmaceutical services Outsourcing Market, by Services, 2016 - 2028 (USD Million)
Table 5 Global Biotechnology & Pharmaceutical services Outsourcing Market, by End Use, 2016 - 2028 (USD Million)
Table 6 North America Biotechnology & Pharmaceutical services Outsourcing Market, by Country, 2016 - 2028 (USD Million)
Table 7 North America Biotechnology & Pharmaceutical services Outsourcing Market, by Services, 2016 - 2028 (USD Million)
Table 8 America Biotechnology & Pharmaceutical services Outsourcing Market, by End Use, 2016 - 2028 (USD Million)
Table 9 The U.S. Biotechnology & Pharmaceutical services Outsourcing Market, by Services, 2016 - 2028 (USD Million)
Table 10 The U.S. Biotechnology & Pharmaceutical services Outsourcing Market, by End Use, 2016 - 2028 (USD Million)
Table 11 Canada Biotechnology & Pharmaceutical services Outsourcing Market, by Services, 2016 - 2028 (USD Million)
Table 12 Canada Biotechnology & Pharmaceutical services Outsourcing Market, by End Use, 2016 - 2028 (USD Million)
Table 13 Europe Biotechnology & Pharmaceutical services Outsourcing Market, by Country, 2016 - 2028 (USD Million)
Table 14 Europe Biotechnology & Pharmaceutical services Outsourcing Market, by Services, 2016 - 2028 (USD Million)
Table 15 Europe Biotechnology & Pharmaceutical services Outsourcing Market, by End Use, 2016 - 2028 (USD Million)
Table 16 The U.K. Biotechnology & Pharmaceutical services Outsourcing Market, by Services, 2016 - 2028 (USD Million)
Table 17 The U.K. Biotechnology & Pharmaceutical services Outsourcing Market, by End Use, 2016 - 2028 (USD Million)
Table 18 Germany Biotechnology & Pharmaceutical services Outsourcing Market, by Services, 2016 - 2028 (USD Million)
Table 19 Germany Biotechnology & Pharmaceutical services Outsourcing Market, by End Use, 2016 - 2028 (USD Million)
Table 20 Asia Pacific Biotechnology & Pharmaceutical services Outsourcing Market, by Country, 2016 - 2028 (USD Million)
Table 21 Asia Pacific Biotechnology & Pharmaceutical services Outsourcing Market, by Services, 2016 - 2028 (USD Million)
Table 22 Asia Pacific Biotechnology & Pharmaceutical services Outsourcing Market, by End Use, 2016 - 2028 (USD Million)
Table 23 Japan Biotechnology & Pharmaceutical services Outsourcing Market, by Services, 2016 - 2028 (USD Million)
Table 24 Japan Biotechnology & Pharmaceutical services Outsourcing Market, by End Use, 2016 - 2028 (USD Million)
Table 25 China Biotechnology & Pharmaceutical services Outsourcing Market, by Services, 2016 - 2028 (USD Million)
Table 26 China Biotechnology & Pharmaceutical services Outsourcing Market, by End Use, 2016 - 2028 (USD Million)
Table 27 India Biotechnology & Pharmaceutical services Outsourcing Market, by Services, 2016 - 2028 (USD Million)
Table 28 India Biotechnology & Pharmaceutical services Outsourcing Market, by End Use, 2016 - 2028 (USD Million)
Table 29 Latin America Biotechnology & Pharmaceutical services Outsourcing Market, by Country, 2016 - 2028 (USD Million)
Table 30 Latin America Biotechnology & Pharmaceutical services Outsourcing Market, by Services, 2016 - 2028 (USD Million)
Table 31 Latin America Biotechnology & Pharmaceutical services Outsourcing Market, by End Use, 2016 - 2028 (USD Million)
Table 32 Brazil Biotechnology & Pharmaceutical services Outsourcing Market, by Services, 2016 - 2028 (USD Million)
Table 33 Brazil Biotechnology & Pharmaceutical services Outsourcing Market, by End Use, 2016 - 2028 (USD Million)
Table 34 Mexico Biotechnology & Pharmaceutical services Outsourcing Market, by Services, 2016 - 2028 (USD Million)
Table 35 Mexico Biotechnology & Pharmaceutical services Outsourcing Market, by End Use, 2016 - 2028 (USD Million)
Table 36 MEA Biotechnology & Pharmaceutical services Outsourcing Market, by Country, 2016 - 2028 (USD Million)
Table 37 MEA Biotechnology & Pharmaceutical services Outsourcing Market, by Services, 2016 - 2028 (USD Million)
Table 38 Biotechnology & Pharmaceutical services Outsourcing Market, by End Use, 2016 - 2028 (USD Million)
Table 39 South Africa Biotechnology & Pharmaceutical services Outsourcing Market, by Services, 2016 - 2028 (USD Million)
Table 40 South Africa Biotechnology & Pharmaceutical services Outsourcing Market, by End Use, 2016 - 2028 (USD Million)


List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity flow analysis
Fig. 9 Volume price analysis
Fig. 10 Market summary, 2020
Fig. 11 Biotechnology & Pharmaceutical services outsourcing market segmentation
Fig. 12 Parent market outlook
Fig. 13 Ancillary market outlook
Fig. 14 Penetration & growth prospect mapping
Fig. 15 Market driver relevance analysis (Current & future impact)
Fig. 16 Market restraint relevance analysis (Current & future impact)
Fig. 17 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 18 Porter’s five forces analysis
Fig. 19 Biotechnology & Pharmaceutical services outsourcing market: Service movement analysis
Fig. 20 Consulting market, 2016 - 2028 (USD Million)
Fig. 21 Regulatory compliance market, 2016 - 2028 (USD Million)
Fig. 22 Remediation market, 2016 - 2028 (USD Million)
Fig. 23 Quality management systems consulting market, 2016 - 2028 (USD Million)
Fig. 24 Auditing and assessment market, 2016 - 2028 (USD Million)
Fig. 25 Regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 26 Clinical trial applications & product registration market, 2016 - 2028 (USD Million)
Fig. 27 Regulatory writing & publishing market, 2016 - 2028 (USD Million)
Fig. 28 Legal representation market, 2016 - 2028 (USD Million)
Fig. 29 Others market, 2016 - 2028 (USD Million)
Fig. 30 Product maintenance market, 2016 - 2028 (USD Million)
Fig. 31 Product design & development market, 2016 - 2028 (USD Million)
Fig. 32 Product testing & validation market, 2016 - 2028 (USD Million)
Fig. 33 Training & education market, 2016 - 2028 (USD Million)
Fig. 34 Others market, 2016 - 2028 (USD Million)
Fig. 35 Pharma market, 2016 - 2028 (USD Million)
Fig. 36 Biotech market, 2016 - 2028 (USD Million)
Fig. 37 Regional market place: Key takeaways
Fig. 38 Regional outlook, 2020 & 2028
Fig. 39 North America market, 2016 - 2028 (USD Million)
Fig. 40 The U.S. market, 2016 - 2028 (USD Million)
Fig. 41 Canada market, 2016 - 2028 (USD Million)
Fig. 42 Europe market, 2016 - 2028 (USD Million)
Fig. 43 The U.K. market, 2016 - 2028 (USD Million)
Fig. 44 Germany market, 2016 - 2028 (USD Million)
Fig. 45 Asia Pacific market, 2016 - 2028 (USD Million)
Fig. 46 Japan market, 2016 - 2028 (USD Million)
Fig. 47 China market, 2016 - 2028 (USD Million)
Fig. 48 India market, 2016 - 2028 (USD Million)
Fig. 49 Latin America market, 2016 - 2028 (USD Million)
Fig. 50 Brazil market, 2016 - 2028 (USD Million)
Fig. 51 Mexico market, 2016 - 2028 (USD Million)
Fig. 52 MEA market, 2016 - 2028 (USD Million)
Fig. 53 South Africa market, 2016 - 2028 (USD Million)

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GV21MC006 )"世界のバイオテクノロジー&製薬におけるサービスアウトソーシング市場2021-2028:サービス別(コンサルティング、規制関連業務)、最終用途別(製薬、バイオテクノロジー)" (英文:Biotechnology & Pharmaceutical Services Outsourcing Market Size, Share & Trends Analysis Report By Service (Consulting, Regulatory Affairs), By End-use (Pharma, Biotech), And Segment Forecasts, 2021 - 2028)はGrand View Research社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。